Navigation Links
'Signature' of chromosome instability predicts cancer outcomes

Microscopic examination of tumor specimens cannot always predict a cancer's aggressiveness, leading to increased interest in molecular approaches to diagnosis. Now, researchers in the Children's Hospital Informatics Program (CHIP) at the Harvard-MIT Division of Health Sciences and Technology report that a genetic profile indicating chromosomal instability -- an increased tendency to develop chromosomal aberrations, critical in cancer development -- is predictive of clinical outcome in a broad range of cancer types.

Using data on gene expression (activity) from 18 previous studies of cancer, representing six cancer types, they found that this genetic profile, or signature, predicted poor clinical outcome in 12 of the populations studied. The study was published online by the journal Nature Genetics on August 20.

"Chromosomal instability is one of the key mechanisms that keeps malignant cell proliferation going," says Zoltan Szallasi, MD, a CHIP researcher and the study's senior investigator. "We have achieved a relatively easy way to measure the level of chromosomal instability in a given tumor sample."

The technique may help in the search for cancer drugs that reduce chromosomal instability -- an approach of increasing interest to researchers -- by making it possible to screen a large number of drugs for efficacy, Szallasi notes. With further development, the team's work could also form the basis of a diagnostic tool that could be used in the clinic.

The human genome is at constant risk for mutations due to environmental insults, errors in gene replication, and other factors that can cause chromosomes to break and bits of DNA to be lost, duplicated or reshuffled to the wrong chromosomes. Cells have repair mechanisms that constantly fix this damage, but when the repair process breaks down, chromosomes become unstable and cancers are more likely to develop.

Chromosomal instability leads to a condition known as aneuploidy,
'"/>

Source:Children's Hospital Boston


Page: 1 2

Related biology news :

1. Found: Missing sequence of the human Y chromosome
2. Variation in womens X chromosomes may explain differences among individuals, between sexes
3. Scientists analyze chromosomes 2 and 4
4. Normal chromosome ends elicit a limited DNA damage response
5. Utah researchers confirm chromosome may harbor autism gene
6. Mouse to man: The story of chromosomes
7. Movement of chromosome in nucleus visualized
8. Sex chromosome genes influence aggression andmaternal behavior, say UVa researchers
9. Researchers use multiphoton microscopy to watch chromosomes in action
10. Short chromosomes put cancer cells in forced rest
11. Researchers attach genes to minichromosomes in maize
Post Your Comments:
(Date:7/8/2008)...o stay fit, do their bit for the environment or av...eir health if they don,t choose the right bicycle....al surgeon Mr Vinod Nargund from St Bartholomew,s ...rnal BJU International . , He says that the pro...ection problems and soreness and skin irritations ...
(Date:7/8/2008)... . , Barcelona, Spain: Couples who need IVF... this will not lead to developmental problems in e...ual conference of the European Society of Human Re...Dr. Karin Middelburg, from the University Medical ... that the study, which looked at the quality of ge...
(Date:7/8/2008)... . , Barcelona, Spain: Children born after ...omb have higher birth weight than those born where...ed to the 24th annual conference of the European S...(Tuesday 8 July). The mothers had longer pregnanci...k of congenital malformations, said Dr. Anja Pinbo...
(Date:7/7/2008)...U.S. coral reef ecosystems are considered to be in...A analysis of the health of coral reefs under U.S....tate of Coral Reef Ecosystems of the United States...that the nation,s coral reef ecosystems, particula... face intense human-derived threats from coastal d...
Breaking Biology News(10 mins):Male cyclists risk sexual problems if they don’t choose the right bike 2IVF does not increase risk of developmental disorders in children 2Children born from frozen embryos weigh more and do better than those born after fresh transfer 2NOAA report states half of US coral reefs in 'poor' or 'fair' condition 2New insight into RA patient priorities and motivators for clinical trial involvement 21796 1New insight into RA patient priorities and motivators for clinical trial involvement 21796 2New insight into RA patient priorities and motivators for clinical trial involvement 21796 3Express Scripts in Binding Agreement with MSC for the Purchase of its Pharmacy Services Division 21792 1Express Scripts in Binding Agreement with MSC for the Purchase of its Pharmacy Services Division 21792 2Express Scripts in Binding Agreement with MSC for the Purchase of its Pharmacy Services Division 21792 3Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 1Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 2Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 3Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 4Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 5Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 6Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 7Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 8Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 9Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 10Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 11Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 12Video 3A Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5982 13Patients Taking Cymbalta 28R 29 Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 2421 1Patients Taking Cymbalta 28R 29 Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 2421 2Patients Taking Cymbalta 28R 29 Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 2421 3Patients Taking Cymbalta 28R 29 Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 2421 4Patients Taking Cymbalta 28R 29 Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study 2421 5
...at the Johns Hopkins Bloomberg School of Public He...r a variety of illnesses using genetically modifie...ctions. Oral adenovirus vaccines have long been pr...ieve their process for constructing a replicating ...nomical vaccines that provide longer-lasting disea...
...eport today in the journal Genome,Research that th...eviously intractable DNA sequence: a 554-kilobase-...man Y chromosome. This sequence,contains eight put...ex-associated height differences and gonadal tumor...f the few holes remaining in the,"finished" sequen...
...ave discovered that a protein that was originally ... resistance is actually a "missing enzyme" from th...cteria to scavenge iron. , The research appears as...he Journal of Biological Chemistry, an American So...al. , Mycobacterium tuberculosis, the causative a...
...pment in the analysis of cancer,has been announced... an,innovative method that enables the rapid advan... in cancer. According to the report,published in t...he,National Academy of Science (PNAS) in collabora...tute, Agilent has developed a specialised,microarr...
Other Biology News:Live Recombinant Adenovirus Vaccine Technique Explored 2Found: Missing sequence of the human Y chromosome 2Found: Missing sequence of the human Y chromosome 3Scientists find missing enzyme for tuberculosis iron scavenging pathway 2Breakthrough Microarray-based Technology for the Study of Cancer 2
(Date:7/8/2008)... BugLab LLC, has introduced the,BugEye 200 Noninva...system,with the widest linear range of any such de...ontinuous, real-time optical density (OD) measurem...applications. The BugEye 200,is designed for use i...ents,and has a sensor that is easily secured to th...
(Date:7/8/2008)...alization of the Revolutionary Ac...ch., July 8 /- Accuri Cytometers Inc.... bench-top flow cytometer systems,today announced...g led by,Fidelity Biosciences and Flagship Venture...ers and Arboretum Ventures also participated in th...
(Date:7/8/2008)... PAREXEL International,Corporation (Nasdaq: PRXL ...,financial results on Wednesday, August 6, 2008 af...t will be available on PAREXEL,s website at, http:...at http://www.prnewswire.com ., PAREXEL will ho.... EDT,on Thursday, August 7, 2008 to discuss the r...
(Date:7/8/2008)...- GeneGo, Inc., the leading,systems biology tools ...s,license to GeneGo products. Unilever uses system...s and skin care product development., "Unilever w...we are,very pleased to continue working with them,...opment. "Unilever is a consumer goods company that...
Breaking Biology Technology:BugLab Launches Noninvasive Biomass Monitor for Continuous, On-Line Measurements 2Accuri Cytometers Completes $13 Million Series C Financing 2Accuri Cytometers Completes $13 Million Series C Financing 3Accuri Cytometers Completes $13 Million Series C Financing 4PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2008 Earnings Release and Conference Call 2Unilever Extends Their GeneGo MetaCore License 2
...eviously reported initiative to establish a citywi...communities of Waukesha, Wauwatosa and Brookfield ...a are already being pitched by Cellnet, the provid...Milwaukee,s network is being built by a different ...stablished so far, the city is essentially leasing...
...student Pengpeng Zhang successfully imaged a piece... centimeter-in thickness, she and her UW-Madison c...ed thinking, the feat should be impossible because...ct electricity. , ,"After she did it, we realized,... thinner than what people normally use," says UW-...
... Third Wave Technologies has settled with a Belg...ng patents. Third Wave will license hepatitis C vi...ndisclosed financial terms. , ,The two companies, ... Wave forged a deal under which Innogenetics was a... line of products in Europe. It was Third Wave,s f...
... First Business Bank plans to launch a remote di...ne County. , ,Companies that purchased the service...over the Internet to the bank, where they would be... that First Business Bank president and COO Michae...c markets. , ,The service would eliminate trips to...
Other Biology Technology:Study explains unexpected conductivity of nanoscale silicon 2Study explains unexpected conductivity of nanoscale silicon 3
UBN-1 (C-20)
Rabbit polyclonal to Neuron navigator 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide conjugated to KLH derived from within residues 1850 to the C-terminus of Mouse Neuron
Mouse HAI-1 Ectodomain MAb (Clone 199732)
pETDuet-1 is designed for the coexpression of two target genes.
Biology Products: